Overview

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) 20 mcg/mL vs Vehicle, in Patients With Sjogren's Dry Eye

Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease (DED) who are under chronic treatment with topical Cyclosporine A (CsA).
Phase:
Phase 3
Details
Lead Sponsor:
Dompé Farmaceutici S.p.A